Camarda Cecilia, Camarda Rosolino, Monastero Roberto
Adult Headache Centre, Department of Clinical Neuroscience, University of Palermo, Palermo, Italy.
Clin Neurol Neurosurg. 2008 Jan;110(1):88-91. doi: 10.1016/j.clineuro.2007.09.002. Epub 2007 Oct 22.
Chronic paroxysmal hemicrania (CPH) is a rare primary headache syndrome, which is classified along with cluster headache and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing as a trigeminal autonomic cephalalgia (TACs). Hemicrania continua (HC) was previously classified as one of the TACs, but in the recent second classification of the International Headache Society this disorder was moved to the group of other primary headaches. Both CPH and HC are characterised by moderate to excruciating pain requiring pharmacological treatment; furthermore, both conditions are characterised by an absolute response to indomethacin, which represents one of the current diagnostic criteria for these two syndromes. Unfortunately, in about one-fourth of cases treatment with indomethacin may cause adverse events, mostly gastrointestinal. We report one subject with CPH and another with HC intolerant to indomethacin, who responded remarkably well to topiramate.
慢性阵发性半侧头痛(CPH)是一种罕见的原发性头痛综合征,它与丛集性头痛以及伴有结膜充血和流泪的短暂性单侧神经痛样头痛发作一同被归类为三叉自主神经性头痛(TACs)。持续性偏侧头痛(HC)曾被归类为TACs之一,但在国际头痛协会最近的第二次分类中,这种疾病被归入其他原发性头痛组。CPH和HC都具有中度至剧痛的特点,需要药物治疗;此外,这两种病症都对吲哚美辛有绝对反应,这是这两种综合征目前的诊断标准之一。不幸的是,在大约四分之一的病例中,吲哚美辛治疗可能会引起不良事件,主要是胃肠道方面的。我们报告了一名患有CPH的患者和另一名对吲哚美辛不耐受的HC患者,他们对托吡酯反应良好。